ADMA Biologics (ADMA) Reports Q4 Loss of $0.58

ADMA Biologics (NASDAQ: ADMA) reported Q4 EPS of ($0.58), versus $0.50 reported last year. Revenue for the quarter came in at $524 thousand, versus $30 million reported last year.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Important Notice to Long-Term Shareholders of ADMA Biologics, Inc. (NASDAQ: ADMA); GeneDx Holdings Corp. (NASDAQ: WGS); Navan, Inc. (NASDAQ: NAVN); and New Era Energy & Digital, Inc. (NASDAQ: NUAI) (F
• Goldman: 'Our top picks include XYZ, KLAR, AFRM, and CHYM'
• Northern Technologies (NTIC) Misses Q3 EPS by 12c